Browsing ODA Open Digital Archive by Author "Brenna, Ida Halvorsen"
Now showing items 1-3 of 3
-
Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up
Gaulen, Zhanna; Saltyte Benth, Jurate; Fadnes, Lars T.; Brenna, Ida Halvorsen; Tanum, Lars Håkon Reiestad (Journal of Substance Abuse Treatment;Volume 135, April 2022, 108656, Peer reviewed; Journal article, 2021-02-15)Introduction: Life satisfaction (LS) in opioid-dependent individuals is lower than in the general population. This study aimed to explore changes in LS during short- and long-term treatment with extended-release naltrexone ... -
Not at all what I had expected: Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study
Brenna, Ida Halvorsen; Marciuch, Anne; Birkeland, Bente; Veseth, Marius; Røstad, Bente; Løberg, Else-Marie; Solli, Kristin Klemmetsby; Tanum, Lars Håkon Reiestad; Weimand, Bente (Peer reviewed; Journal article, 2021)Background: Extended-release naltrexone (XR-NTX), an opioid antagonist, has demonstrated equal treatment outcomes, in terms of safety, opioid use, and retention, to the recommended OMT medication buprenorphine. However, ... -
Patients with Opioid Use Disorder Choosing Treatment with Extended-Release Naltrexone: A 6-Month Naturalistic Study
Brenna, Ida Halvorsen; Waleur, Karin Merethe; Saltyte Benth, Jurate; Solli, Kristin Klemmetsby; Mordal, Jon; Løberg, Else-Marie; Weimand, Bente; Tanum, Lars Håkon Reiestad (Peer reviewed; Journal article, 2024)Introduction: The treatment efficacy of extended-release naltrexone (XR-NTX) for opioid use disorder (OUD) has been demonstrated in several studies, but not in naturalistic settings where opioid agonist treatment (OAT) is ...